|Bid||4.3240 x N/A|
|Ask||4.3480 x N/A|
|Day's Range||4.3000 - 4.4000|
|52 Week Range||3.9100 - 5.0990|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nanoform's half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: "to acquire more new customers in 2020 than in 2019" achieved in July.
Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on September 1, 2020 at 10 am Helsinki time to elect Cynthia Schwalm as a new board member. The notice to the EGM was published simultaneously with this release. Cynthia, a renowned Biotechnology CEO and pharmaceutical leader, began her career as an Oncology and Critical Care Nurse at the Albert Einstein Medical Center & Rutgers University Camden Medical Center, where she developed a patient-focused perspective. She then honed her leadership skills over 30+ years by orchestrating, in executive positions, the activities of top-tier global pharmaceutical organisations in the US, such as J&J; and Amgen. Further career highlights include her role as President and CEO of Ipsen and Eisai's North American Divisions.